Background: For several decades, the introduction of AntiRetrovirals (ARVs) has improved the symptomatology of People Living with HIV (PLHIV), a spectacular reduction in morbidity and mortality, an improvement in life expectancy and quality of life of PLHIV. Objective: The objective of this study was to determine the profile of PLHIV initiating AntiRetroViral Treatment (ART) in the era of Dolutegravir in Kinshasa. Methods: Cross-section of a prospective cohort to determine the profile of PLHIV initiating ART in Kinshasa. The inclusions were from October 04, 2021 to February 15, 2022. Confirmation of the diagnosis was carried out by Nested PCR. The inclusion criteria were: being at least 18 years old, confirmed HIV positive, naïve to ART, consenting and having signed an informed consent. The parameters of interest followed for the present study were: age, sex, religion, level of study, marital status, occupation, height, weight, body mass index (BMI), the clinical profile, the opportunistic infections as well as the para-clinical assessment (biochemistry and molecular biology). Results: 67 (56.3%) women and 52 (43.7%) men were included, thus 119 patients, all confirmed positive for HIV by Nested PCR on the gag, pol and env regions. The average age of the patients included is 39.87 ± 12.36 years and the most represented age group is that of 36 to 45 years with 37 patients (31.9%). The average height was 1.66 ± 0.08 meters, with an average weight of 56.41 ± 13.30 kg, giving an average Body Mass Index (BMI) of 21.54 ± 5.17 kg/m2. The majority of patients were married (46.1%), of Protestant religion (70.7%), with secondary education (66.7%), and working in the informal sector (29.4%). 49 patients (41.5%) were in clinical stage 3 and 55 patients (47.0%) had a normal clinical status. Malaria (45.4%) and tuberculosis (29.4%) were the most common Opportunistic Infections. The mean values of the patients’ assessed biochemical parameters were within the ranges. The median VL value was 4.16 log10 RNA copies/ml. Subtype A (20.2%) is dominant. Mutations K65R (2 cases), T69P/N (5 cases), K70R (9 cases) and M184V (8 cases) were listed. Conclusion: In Kinshasa, PLHIV start ART late. The biochemical parameters evaluated are within normal ranges, with high VLs. Subtype A remains predominant and there are mutations conferring resistance to ART.
References
[1]
United Nations AIDS Program (UNAIDS) (2020) Country Factsheets: Democratic Republic of the Congo. https://www.unaids.org/en/regionscountries/countries/democraticrepublicofthecongo
[2]
Organisation Mondiale de la Santé (OMS) (2012) Améliorer l’accès aux Traitements ARVs dans les pays à ressources limitées.
[3]
Programme National de Lutte contre le VIH/SIDA et les IST (PNLS). Ministère de la Santé Publique. République Démocratique du Congo (2017) Guide National de Prise en Charge intégrée du VIH.
[4]
Programme National de Lutte contre le VIH/SIDA et les IST (PNLS). Ministère de la Santé Publique. République Démocratique du Congo (2019) Révision du Guide National de Prise en Charge.
[5]
Organisation Mondiale de la Santé (OMS) (2016) Mettre fin au VIH/SIDA d’ici 2030; Cadre d’action dans la région Africaine de l’OMS. 2016-2022.
[6]
Programme National de Lutte contre le VIH/SIDA et les ISTs, Ministère de la Santé Publique et Hygiène, République Démocratique du Congo (2021) Guide de la prise en charge intégrée du VIH/SIDA en République Démocratique du Congo. Révision.
[7]
Kamangu, N.E., Bwiri, B.B. and Mvumbi, L.G. (2019) Clinical and Paraclinical Profile of People Living with Human Immunodeficiency Virus on Second Line Treatment in Kinshasa, Democratic Republic of Congo. Open Access Library Journal, 6, e5499. https://doi.org/10.4236/oalib.1105499
[8]
Mbula, M.M.K., Situakibanza, H.N.T., Mananga, L.G., Longokolo, M.M., Mandina, N.M., Mayasi, N.N., Mbula, M.M., Bepouka, B., Amaela, E.N., Tshilumba, D.N., Odio, O., Nkodila, A. and Longo Mbenza, B. (2020) Profil clinique et biologique des Personnes Vivant avec le VIH/SIDA suivies dans le Service des Maladies Infectieuses des Cliniques Universitaires de Kinshasa, République Démocratique du Congo. Revue Malienne d’Infectiologie et de Microbiologie, 15, 21-29. https://doi.org/10.53597/remim.v15i2.1727
[9]
Kimpiatu, J.-P.M., Nkodila, A.N., Tshimpi, A.W.Y., Mbendi, C.N., Ndarabu, T., Matimbo, J.J., et al. (2022) Clinical, Biological, Immunological and Therapeutic Profile of Patients Co-Infected with HIV-HBV and/or HCV in Kinshasa, in the Democratic Republic of the, Congo: Multicenter Cross-Sectional Study. Open Journal of Gastroenterology, 12, 107-118. https://doi.org/10.4236/ojgas.2022.124011
[10]
Losenga, L.O., Dikati, N.M., Bongenya, B.I., Ntumba, T.K., Booto, G.I., Dembo, R.D., et al. (2022) Sociodemographic and Anthropometric Profile of People Living with Human Immunodeficiency Virus Starting Treatment in Kinshasa, Democratic Republic of the Congo. Open Access Library Journal, 9, e9056. https://doi.org/10.4236/oalib.1109056
[11]
Kamangu, N.E., Mayemba, C., Mbikayi, S., Ndarabu, A., Kalala, R.L., Mvumbi, G.L. and Vaira, D. (2014) Implementation of a Classic Nested PCR DNA for HIV Diagnosis in Kinshasa. International Journal of Collaborative Research on Internal Medicine and Public Health (IJCRIMPH), 6, 145-151.
[12]
Bongenya, B.I., Bulanda, B.I. and Kamangu, E.N. (2020) Comparison of Rapid Diagnosis Test and Nested PCR for HIV Diagnosis in Kinshasa. Open Access Library Journal, 7, e6325. https://doi.org/10.4236/oalib.1106325
[13]
QIAGEN (2010) QIAamp® DNA Mini and Blood Mini Handbook. 3rd Edition.
[14]
QIAGEN (2010) QIAamp® RNA Mini and Blood Mini Handbook. 3rd Edition.
[15]
Kamangu, N.E., Chatté, A., Boreux, R., Kalala, L.R., Mvumbi, L.G., De Mol, P., Vaira, D. and Hayette, M.P. (2014) Implementation of an In-House Quantitative Real-Time PCR for Determination of HIV Viral Load in Kinshasa. Open Access Library Journal, 1, e855. https://doi.org/10.4236/oalib.1100855
[16]
Kamangu, N.E., Chatté, A., Boreux, R., Susin, F., Kalala, L.R., Mvumbi, L.G., De Mol, P., Hayette, M.P. and Vaira, D. (2015) Comparison of an In-House Quantitative PCR and COBAS Ampliprep/TaqMan Roche for Determination of Viral Load for HIV Type 1 Non-B. Open Access Library Journal, 2, e1402. https://doi.org/10.4236/oalib.1101402
[17]
Kamangu, N.E. (2022) Caractérisation Moléculaire du VIH-1 à Kinshasa: Caractérisation Moléculaire du Virus de l’Immunodéficience Humaine de Type 1 et Suivi Thérapeutique des patients pris en charge à Kinshasa/République Démocratique du Congo. Editions Universitaires Européennes.
[18]
Kamangu, N.E., Wumba, D.M.R., Situakibanza, N.T.S., Lukusa, T.P., Kapend, K.L., Mvumbi, L.G., Hayette, M.P. and Kalala, L.R. (2018) Molecular Epidemiology of Human Immunodeficiency Virus Type 1 and Therapeutic Monitoring of Patients Treated in Kinshasa/Democratic Republic of the Congo. International Journal of HIV and AIDS Research, 2, 6-11.
[19]
Ministère du Plan et Suivi de la Mise en œuvre de la Révolution de la Modernité et Ministère de la Santé Publique, République Démocratique du Congo (2014) Enquête Démographique et de Santé 2013-2014 (EDS 2013-2014).
[20]
Kamangu, N.E., Bulanda, I.B., Bongenia, I.B., Botomwito, T.H., Mvumbi, L.G., De Mol, P., et al. (2015) Virological Profile of Patients Infected with HIV Starting Antiretroviral Treatment in Kinshasa. Open Access Library Journal, 2, e1564. https://doi.org/10.4236/oalib.1101564
[21]
Bulanda, B.I., Kateba, E.T., Bongenia, B.I., Kasongo, V.N., Kingombe, M.A. and Kamangu, E.N. (2018) Sociodemographic and Anthropometric Profile of Positive HIV Patients in Early Traditional Treatment: Case of the Bonkoko Center. Open Access Library Journal, 5, e4555. https://doi.org/10.4236/oalib.1104555
[22]
Mwelo, L.J., Ngimba, M., Nzingula, P.O., Luvandu, M.M., Misengabu, M.N. and Kodondi, K.K.F. (2022) Prévalence du VIH lors des Examens Prénuptiaux. Congo Sciences, 10, 33-36.
[23]
Demart, S. (2008) Le combat pour l’intégration des églises issues du Réveil congolais (RDC). Remi, 24, 147-165. https://doi.org/10.4000/remi.4840
[24]
Matangila, A. (2006) Pour une analyse du discours des Eglises de réveil à Kinshasa. Civilisations, 54, 76-84. https://doi.org/10.4000/civilisations.343
[25]
Mussa, R.M., Nkodila, A.N., Kiala, N.A., Muilu, J.M. and Mananga, G.L. (2021) Sociodemographic and Psychological Determinants of Neurocognitive Disorders in People Living with HIV on TARVs in Kinshasa: Cross-Sectional Study. International Journal of HIV/AIDS Prevention, Education and Behavioral Science, 7, 61-65. https://doi.org/10.11648/j.ijhpebs.20210702.12
[26]
Booto, G.I., Selenge, S.M., Bongenya, B.I., Ntumba, T.K., Losenga, L.O., Dikati, N.M., et al. (2022) Clinical Profile of People Living with Human Immunodeficiency Virus Starting Treatment in Kinshasa, Democratic Republic of Congo. Open Access Library Journal, 9, e9134. https://doi.org/10.4236/oalib.1109134
[27]
Ntumba, K.T., Bongenya, I.B., Losenga, L.O., Booto, G.I., Dikati, N.M., Dembo, R.D., et al. (2022) Opportunistic Infections in People Living with Human Immunodeficiency Virus Initiating Antiretroviral Therapy in Kinshasa, Democratic Republic of Congo. Austin Journal of Infectious Diseases, 9, Article No. 1073.
[28]
Situakibanza, H.N., Odio, W., Ekila, B., Lukina, T. and Kintoki, F. (1996) Etiology of Fever in AIDS: About 64 Years. Medical Panorama, 14, 842-845.
[29]
Kamangu, N.E., Situakibanza, N.H., Mvumbi, L.G., Kakudj, I.L., Tshienda, T.D. and Mesia, K.G. (2012) Profiles of Opportunistic Infections in People Living with HIV Followed at the Military Hospital of Kinshasa Reference (Camp Kokolo), DRC. Retrovirology, 9, P146. http://www.retrovirology.com/content/9/S1/P146
[30]
Kamangu, N.E., Muhindo, M.H., Wapa-Kamangu, W.C. and Situakibanza, N.T.H. (2015) Prevalence of Malaria Infection among People Living with HIV in Kinshasa. Open Access Library Journal, 2, e1077. https://doi.org/10.4236/oalib.1101077
[31]
Kamangu, E.N. (2016) Human Immunodeficiency Virus Type 1 and Type 2 Coinfection Rate in Kinshasa Patients. MJ HIV, 1, Article No. 009.
[32]
Bongenya, B.I., Bulanda, B.I., Bukongo, R.N., Chuga, D., Botomuito, H.T., Kabasele, J.-Y.D. and Kamangu, E.N. (2022) Prevalence of Opportunist Infections among the Professionals Sex Workers and Their Customers Living with the VIH under ARV in Kinshasa. Open Access Library Journal, 9, e7927. https://doi.org/10.4236/oalib.1107927
[33]
Bongenya, B.I., Sombo, M.T.A.S., Bumoko, G.M.M., Kabengele, B.O., Kodondi, F.K.K., et al. (2023) Biological Profile of People Living with Human Immunodeficiency Virus Starting Treatment in Kinshasa, Democratic Republic of the Congo. World Journal of AIDS, 13, 1-10. https://doi.org/10.4236/wja.2023.131001
[34]
Kamangu, N.E., Kalala, L.R., Mvumbi, L.G. and Mesia, K.G. (2012) Comparative Analysis of Serum Protein Electrophoresis’ Profiles of People Infected with HIV and Those Not Infected with HIV in Kinshasa. International Journal of Collaborative Research on Internal Medicine & Public Health, 4, 876-884.
[35]
Kleinmans, S., Bush, M.P., Hall, L., Thomson, R., Glynn, S., Gallahan, D., et al. (1998) False Positive HIV-1 Test Results in Low-Risk Screening Setting of Voluntary Blood Donation. JAMA, 280, 1080-1085. https://doi.org/10.1001/jama.280.12.1080
[36]
Bertisch, B. and Vernazza, P. (2010) Infection par le VIH-Le dépistage précoce limite les dommages pour l’individu et la société. Forum Médical Suisse, 10, 798-801. https://doi.org/10.4414/fms.2010.07337
[37]
Bongenya, B.I., Tshinguta, C.L., Sombo, M.T.A.S., Bumoko, G.M.M., Kabengele, B.O., Mesia, G.K. and Kamangu, E.N. (2023) Profil Virologique et Moléculaire des Personnes Vivant avec le Virus de l’Immunodéficience Humain débutant le Traitement à base de Dolutegravir à Kinshasa, République Démocratique du Congo. Sous-Presse.
[38]
Wateba, I.N., Patassi, A.A., Balaka, A. and Tidjani, O. (2013) Viral Characteristic of HIV Infected Patients Naïf of Anti-Retroviral Therapy with CD4+ T Lymphocytes Rate Greater than 350 per Microliter of Blood in Lomé, Togo. World Journal of AIDS, 3, 364-366. https://doi.org/10.4236/wja.2013.34047
[39]
Jordan, M.R., Winsett, J. and Tiro, A. (2013) HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels. WJA, 3, 71-78. https://doi.org/10.4236/wja.2013.32010
[40]
Loukou, Y.G., Zinzendorf, N.Y., Kouadio, H., Dje, L., Cablan, M.A., Lathro, S.J. and Akoua Koffi, M.C. (2012) Genetic Diversity and Antiretroviral Drug Resistance among Drug-Naïve HIV-1 Infected Pregnant Women Attending Antenatal Clinics in Abidjan, Côte d’Ivoire. WJA, 2, 57-63. https://doi.org/10.4236/wja.2012.22008
[41]
Kamangu, N.E., Kabututu, Z.P., Mvumbi, L.G., Kalala, L.R. and Mesia, K.G. (2013) Genetic Diversity of Human Immunodeficiency Virus Type 1 in the Democratic Republic of Congo: A Review of Available Data. International Journal of Collaborative Research on Internal Medicine and Public Health, 5, 295-309.
[42]
Kamangu, E.N. (2020) Diversité Génétique du VIH à Kinshasa, République Démocratique du Congo: Défis d’une dynamique évolutive. Editions Universitaires Européennes.
